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Bronchiolitis Obliterans Syndrome (BOS) complicates the course of many lung transplant recip-
ients. It carries significant risk of morbidity and mortality, but its course is difficult to charac-
terize. We evaluated the prognostic utility of the 6 min walk test (6MWT) obtained after the
onset of BOS in 42 patients. This was compared to the prognostic significance of changes in
the FEV1. The median time between the onset of BOS and the 6MWTwas 109 days. The median
decline in the FEV1 from baseline to BOS onset was 25.7%, while the median change over the
ensuing 3 months was 12.5%. Neither of these was predictive of subsequent mortality. The
6MWT yielded averages in the resting saturation, lowest saturation, distance walked and
maximal Borg scores of 97%, 90.2%, 323 m and 2.35, respectively. The best of these parameters
in discriminating survival was the distance. Patients who walked further than 330 m had
a median survival of 1178 days versus 263 days for those who walked less (p< 0.0001). We
conclude that the 6MWT provides important prognostic information in patients with BOS and
might perform better than spirometry. Use of this test might allow different clinical pheno-
types to be discerned.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Lung transplantation is a therapy that is reserved for
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9 Elsevier Ltd. All rights reservedhave failed all other forms of therapy.1 It is fraught with the
potential for a multitude of complications including chronic
rejection.2,3 The pathologic correlate of chronic rejection
is thought to be bronchiolitis obliterans (BO). There are no
proven effective therapies for BO and management is
geared towards its prevention and early detection. The
diagnosis of BO usually requires a surgical lung biopsy since
transbronchial biopsies lack sufficient sensitivity to suffice
as a diagnostic tool. To avoid subjecting patients to
unnecessary biopsies when the a priori suspicion is high for.
6MWT provides important prognostic information in patients with BOS 1817BO, the International Society for Heart and Lung Trans-
plantation (ISHLT) defined the physiologic entity of bron-
chiolitis obliterans syndrome (BOS) in 1993, with
a subsequent update published in 2002.4,5 BOS is defined by
a permanent 20% reduction in the patients’ FEV1 from their
prior baseline without other apparent cause. This baseline
is defined as the average of the two highest FEV1s obtained
at least 3 weeks apart.
There is now a growing recognition of different BOS
phenotypes with varying onsets, course, and prognoses.6e9
BOS has also been characterized by different airway and
bronchoalveolar lavage (BAL) cellular expression.10e13 It is
highly likely that BOS encompasses a number of different
entities and potentially different etiologies, some of which
may be immunologic and others non-immunologic.14
Different physiologic phenotypes have also previously been
described, but these have been mostly based on patients’
pulmonary function changes, specifically the FEV1.
The 6 min walk test (6MWT) has been used in many
different forms of advanced lung disease to define the
functional ability of patients, assess their oxygen needs and
has also been found to be useful in discerning prognosis.15e
18 Determining the prognosis of BOS is very important for
patient counseling and disease management. We therefore
attempted to assess the prognostic utility of the 6MWT in
lung transplant recipients with BOS and to compare this to
the commonly used FEV1 in determining subsequent
outcomes.Methods
We performed a retrospective analysis of serial pulmonary
function tests (PFTs) and 6MWTs in lung transplant recipi-
ents who developed BOS in the time period from 2000 to
2006. The goal of the study was to assess the prognostic
utility of the 6MWT in patients who developed BOS during
the defined study period. The study group therefore
included patients transplanted in the 6 years time frame,
but also included patients transplanted prior to 2000 if they
met BOS criteria during the study period.
Our lung transplant programs protocol mandates that
patients be seen as outpatients weekly for the first month
after discharge, biweekly for 2 months and then monthly for
the first year. After the first year, they are seen every third
month or more often if clinically indicated. All patients have
spirometry performed with each clinic visit. The prediction
equations of Knudsen et al. are used for all spirometric
maneuvers which are performed per the American Thoracic
Society (ATS) standards.19 For the purposes of this study,
chronic allograft dysfunction (CAD) was defined by patients
meeting BOS physiologic criteria, with or without a new
radiographic pleuroparenchymal process. BOS was defined
according to the ISHLT recommendations; specifically
patients had to have a permanent 20% or greater reduction
in the FEV1 from the prior established baseline in the
absence of an identifiable cause, including any restrictive
process.5 Patients were categorized based on their initial
BOS-qualifying FEV1 into stage 1 (FEV1 65e79% of baseline),
stage 2 (FEV1 50e64% of baseline) or stage 3 (FEV1< 50% of
baseline) BOS. Changes in the patients’ PFTs over the 3
months post-BOS onset were also assessed.After patients qualify as having BOS, a 6MWT is obtained
to assess patient’s functional status and the possible need
for oxygen therapy. All patients are walked on room air
unless their resting oxygen saturation is <88%. In such
cases, they are placed on oxygen which is then titrated up
during the course of the 6MWT to maintain a saturation of
>90%. The following data was extracted from the 6MWT
after the onset of BOS: the distance walked, the baseline
oxygen saturation (SpO2baseline), the lowest oxygen satu-
ration (SpO2 nadir) and the maximal Borg dyspnea score
during the walk. In addition, the distance-saturation
product (DSP) was calculated. This is the product of the
lowest oxygen saturation expressed as a fraction and the
distance walked.20
The primary endpoint of the study was patient mortality.
This was discerned from our Program’s lung transplant
database and the Social Security Death Index. The severity
of BOS at the time of its onset was assessed as a predictor
of survival. Parameters from the initial 6MWT obtained
after patients had qualified as having BOS were also
assessed as predictors of subsequent mortality. These
included the distance walked, the maximal Borg score, the
SpO2baseline, SpO2nadir and the SpO2 change. The study
was approved by the Hospital Institutional Review Board.
Statistics
Continuous data are presented as mean and range or
standard deviation. Categorical data are presented as
frequency and percent. Cumulative probability of death
after post-bronchiolitis obliterans syndrome was calculated
using KaplaneMeier curves with significance testing by the
log-rank test. Cox proportional hazard modeling was
utilized to generate hazard ratios (HR) and 95% confidence
intervals (CI) to assess the association of select PFTs and
6MWT data on patient survival. This modeling was per-
formed using categories of 50 m for the walk distance and
10% for the FEV1. All statistical analyses were conducted
using GraphPad Prism (Version 4.0, San Diego CA) and SAS
9.2 (Carey, NC).
Results
In the 6 years time period of the study, there were 43
patients who developed chronic allograft dysfunction as
defined by a permanent 20% or greater reduction in the
FEV1 in whom there was 6MWT data available after the
diagnosis was established. The diagnosis of BOS was
confirmed in 42/43 patients by reviewing their radiographic
studies at the time of diagnosis. Specifically, at the time of
diagnosis, patients either had a clear chest X-ray (CXR)
and/or CAT scan (NZ 35) or an old stable radiographic
abnormality (NZ 7). Only one of the 43 patients had new
progressive interstitial infiltrates and therefore was not
regarded as having BOS. Of the 42 patients, there were 7
bilateral (BLTx) and 35 single lung transplant recipients
(SLTx). The demographics of the final cohort are shown in
Table 1.
The time interval from transplant to the first of the two
sets of PFTs that defined their baseline FEV1 was 408 days
(range: 18e1472 days). The time interval fromattaining their
Table 1 Demographics of the study cohort.
NZ 42
Age (years), mean SD 53.1 11.2
Female, N (%) 17 (40.5)
Caucasian N (%) 33 (78.6)
Primary disease N (%)
IPF 24 (57.1)
COPD 9 (21.4)
Sarcoidosis 5 (11.9)
Other 4 (9.5)
Bilateral lung
recipient N (%)
7 (16.7)
Single lung
recipient N (%)
35 (83.3)
Baseline FEV1% predicted 70.7 19.9
Baseline FVC % predicted 70.6 19.6
Time to BOS (years) 3.3 1.9
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Figure 2 Outcomes for those patients with BOS who had
a >12.5% decrement in their FEV1s compared to those whose
subsequent FEV1 decline was <12.5% in the 3 months after the
onset of BOS.
1818 S.D. Nathan et al.maximal lung function to the onset of BOS was 758 days
(range: 69e2546 days). The average baseline FVC was
2.78 0.91 (70.9 19.6%) and the FEV1 was 2.25 0.70
(70.8 19.39%). For the SLTx patients, the baseline FVC was
2.63 0.8 L (70.1 20.18%) and the FEV1 was 2.09 0.58
(69.08 19.14%), while for the BLTx recipients it was
3.55 1.08 (75 17%) and 3.00 0.80 (79.6 19.56%),
respectively.
The median decline in the FEV1 from the baseline that
defined the onset of BOS was 25.71%. The majority of
patients (34/42 or 81%) qualified as BOS stage 1, while 5
(12%) and 3 (7%) patients qualified as BOS stages 2 and 3,
respectively. Since most patients had BOS stage 1 at the
time of BOS onset, comparison of groups was performed by
combining BOS stages 2 and 3. BOS stage at the time of BOS
onset was not predictive of subsequent survival (Fig. 1).
When patients were dichotomized by the median change in
the FEV1, this similarly did not discriminate subsequent
survival (p< 0.76). Changes in the patient’s FEV1 over the 3
months post-BOS onset also did not discriminate survival.
The median decrement in the FEV1 for the 3 months period
after the diagnosis of BOS was 12.5% and the survival for
those patients above and below this threshold is shown in
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Figure 1 Comparison of outcomes between patients with
initial BOS stage 1 and those with initial BOS stage 2 or 3.The mean time interval between the onset of BOS and
the first 6MWT performed thereafter was 109 days (ran-
ge:0e734), while the median time was 43 days. Apart from
one patient, all the patients were walked on room air. The
one patient who had a resting oxygen saturation< 88% was
walked on 2 L/min via nasal cannula. The average resting
saturation, lowest saturation, distance walked and maximal
Borg scores at the time of BOS diagnosis were
97.04 2.08%, 90.21 5.27%, 322.88 118.8 m and
2.35 1.95, respectively. The distance walked correlated
with subsequent survival. The median 6MWT distance for
the group was 340 m. Those patients who walked further
than this had a median survival of 1178 days compared to
438 days for those who walked less (p< 0.001) (Fig. 3). The
best cut point to discern survival appeared to be a 6MWT
distance of 300 m. For those patients who walked further,
the median survival was 1178 days versus 263 days for those
who walked less (p< 0.0002). The 1 year survival for
patients who walked >300 m was 100% versus 38.46% for
those who walked <300 m (p< 0.01). Oxygen saturation at
baseline, the degree of desaturation and the lowest oxygen
saturation did not appear to discern subsequent survival.
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Figure 3 Survival of BOS patients based on the initial 6MWT
distance dichotomized by the median distance of 340 m.
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Figure 4 Survival of BOS patients with 6MWT data available
within 3 months of BOS diagnosis, dichotomized by the median
distance of 335 m.
6MWT provides important prognostic information in patients with BOS 1819to <89% during the 6MWT which still failed to reach
significance in discriminating survivors from non-survivors
(p< 0.10). The DSP did not perform any better than the
distance alone.
A subgroup analysis was performed of those patients
who had 6MWT data within 3 months after the onset of BOS.
Twenty-nine patients met this criterion with similar results
to the entire cohort. The median 6MWT distance was
335 m. Those patients who walked less than this had
a median survival of 263 days compared to 1178 days for
those who walked further (Fig. 4). The SpO2 nadir for this
subgroup did correlate with survival; those patients who
desaturated <90% had a median survival of 438 days
compared to 1178 days for those whose SpO2 remained
90% during the 6MWT (p< 0.034) (Fig. 5). The DSP per-
formed equivalently to the 6MWT distance; the median DSP
of the subgroup was 300 which discerned the same patients
as the 6MWT distance of 335 m.
Proportional hazards modeling using 50 m increments
revealed a significant protective effect for distance ach-
ieved during the 6MWT (HR: 0.63; 95% CI: 0.45e0.87) but no
association was observed for the change in FEV1 (using 10%
decrements) from baseline to BOS diagnosis and survival
(HR: 1.05; 95% CI: 0.67e1.66). Similarly, there was no0 250 500 750 1000 1250
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Figure 5 Survival of BOS patients with 6MWT data available
within 3 months of BOS diagnosis, dichotomized by those who
desaturated to <90% during the 6MWT compared to those
whose lowest oxygen saturation remained 90%.association observed between the subsequent change in
FEV1 over the 3 months after BOS onset and survival (HR:
1.23; 95% CI: 0.89e1.71). When the 6MWT distance was
dichotomized by the median distance, patients with a dis-
tance< 340 m were at a significantly increased risk of death
(HR: 6.29; 95% CI: 1.88e21.03). This increased risk of death
remained significant despite adjustment for the change in
FEV1 from baseline to BOS diagnosis (HR: 6.04; 95% CI: 1.78e
20.51). When the monthly change in FEV1 was dichotomized
by the median of 12.5%, patients with> 12.5% change in
FEV1 were not found to be at increased risk of mortality (HR:
1.14; 95% CI: 0.34e3.76) despite adjustment for 6MWT
distance (HR: 5.96; 95% CI: 1.62e21.96).Discussion
Bronchiolitis obliterans syndrome (BOS) complicates the
course of many patients after lung transplantation. It is the
major cause of morbidity and mortality beyond the first year
after transplantation. We demonstrate that data from the
6MWT obtained soon after the diagnosis of BOS provides
important prognostic information. Of the parameters
assessed, the distance walked appeared to impart the best
prognostic information as demonstrated by KaplaneMeier
survival analysis aswell as Cox proportional hazardsmodeling.
It is commonly held that BO is the pathologic correlate of
chronic allograft rejection.2 There is no proven effective
therapy for BOS and management is usually directed towards
its prevention, as well as augmenting immunosuppression and
minimizing complications, such as infections.2 BOS can have
a highly variable course with different clinical patterns of
presentation and progression having been reported.6e9
Patientshavealsobeencategorizedbasedonbronchoalveolar
lavageneutrophilia.10e13 It is not clear that all casesofBOSare
BO and that all BO is necessarily immunologically related.14
Therefore it is becoming increasingly important to recognize
different BOS phenotypes, not only for prognostic purposes,
but also in the design and implementation of clinical treat-
ment trials.
The 6MWT has been used extensively as a simple non-
invasivemeasure of patients’ functional status and to provide
an assessment of oxygen needs with activity. It has also since
been found to impart important prognostic information in
many forms of advanced lung disease.16e18 In this regard, the
6MWThasbeensuggested tobemoreuseful than standardPFT
measurements in a number of disease conditions.20e22
The 6MWT has also been used commonly in potential lung
transplant recipients and for this broad category of patients
has been found to be an important prognostic indicator.
Indeed the distance walked has been incorporated in the
United Network for Organ Sharing (UNOS) lung allocation
score for all listed lung transplant candidates. It has not as
yet however been assessed as a prognostic indicator in
patients post-lung transplantation. To our knowledge, this is
the first report of the prognostic utility of the 6MWT in
patients who develop BOS post-lung transplantation. We
demonstrate that it provides more accurate prognostic
information than the commonly used FEV1 or changes in the
FEV1 over the 3 months post-BOS onset. It is the distance
component of the 6MWT that appears to provide the best
prognostic information. The SpO2 nadir did not appear to add
1820 S.D. Nathan et al.further prognostic information although this was also signif-
icantly associated with outcomes. The distance-saturation
product also did not improve the prognostic accuracy over
the distance alone.
It is not altogether surprising that the 6MWT performs
better than PFT parameters since this has previously been
demonstrated in other forms of advanced lung disease.
Rather than a single static lung volume measurement, the
6MWT has the advantage of providing a global assessment
of patient’s functional status and therefore enables the
effects of other comorbidities to be accounted for. For
example, patients with BOS might develop associated
pulmonary hypertension or diastolic dysfunction which
might impact on their prognosis and 6MWT, but might not
be captured by changes in the FEV1. Furthermore, those
patients who are functionally impaired from other comor-
bidities are more likely to have poorer outcomes. Similar to
what is seen in COPD, there may be a subgroup of patients
with BOS, who have very low FEV1s, but might otherwise
survive for many years.23 This group may be differentiated
by their relatively well-preserved functional status. One
entity that might cause such a physiologic scenario is
bronchomalacia which can be seen in lung transplant
recipients but which might not be discernable from BO
based on PFT changes alone.24,25 Post-transplant 6MWTs
might have an important role in the decision making
process with regards to retransplantation among those
select recipients who are appropriate candidates. It
appears that a distance of 300e335 m might be especially
useful in determining the optimal timing of listing for
retransplantation. Specifically, those who walked more
demonstrated a greater one year survival, while those who
walked less did significantly worse than might be expected
with a retransplant.
It appears therefore that the 6MWT is a valuable clinical
prognostic adjunct that should be assessed in all patients
with BOS. It does allow physiologic phenotypes with
distinctly different outcomes to be identified. Whether
these physiologic phenotypes correlate with different
etiologic, pathologic or cellular/cytokine entities remains
to be determined. The prognostic value of the 6MWT also
has implications with regards to potential contributory
components to mortality in patients with BOS. Specifically,
systemic effects, deconditioning and other comorbidities
may all play important roles.
Our study has a few limitations. First, not all patients
had 6MWT assessed in a standardized temporal fashion
after the onset of BOS. Therefore the 6MWTs that were
analyzed were obtained at varying time intervals after the
onset of BOS. However, our subgroup analysis of those
patients with 6MWT within 3 months of BOS onset provided
similar results with regards to the prognostic value of the
distance walked. Indeed, although the numbers were
smaller in this subgroup, the SpO2 nadir did reach signifi-
cance whereas it was not a significant predictor in the
larger group with the longer temporal intervals. Also, the
6MWT performed within 3 month of BOS onset performed
better as a prognostic tool in comparison to spirometry.
Moreover, it also outperformed the change in the FEV1 over
the 3 month period from BOS onset. This underscores the
superiority of the 6MWT over spirometry in discerning
outcomes.In conclusion, our study demonstrates that the 6MWT
imparts important prognostic information in lung transplant
recipients who develop BOS. This simple test of function-
ality might perform better in this regard than standard
pulmonary function measures. Although the FEV1 defines
the onset of BOS, it appears important to obtain a 6MWT in
all such patients as this will provide important information
about the possible need for oxygen as well as counseling
with regards to expected outcomes. The 6MWT might also
be important in the design and implementation of strate-
gies for the prevention of BOS and future studies of
potential therapies.
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